Tromantadine: Inhibitor of early and late events in herpes simplex virus replication

K. S. Rosenthal, M. S. Sokol, R. L. Ingram, R. Subramanian, R. C. Fort

Research output: Contribution to journalArticlepeer-review

62 Scopus citations


Unlike amantadine (1-adamantanamine), tromantadine (N-1-adamantyl-N-[2-(dimethyl amino)ethoxy]acetamide hydrochloride) inhibits herpes simplex virus type 1 (KOS strain)-induced cytopathic effect and virus replication with limited toxicity to the cells. Vero and HEp-2 cells tolerated up to 2 mg of tromantadine per 2 x 106 cells for 24-, 48-, or 96-h incubation periods with little change in cell morphology. Treatment of the cells with 10 to 50 μg of tromantadine reduced herpes simplex virus-induced cytopathic effect. Treatment with 100 to 500 μg of tromantadine inhibited herpes simplex virus-induced cytopathic effect and reduced virus production. Complete inhibition of virus production was observed with treatments of 500 μg to 1 mg. The antiherpetic activity of tromantadine was dependent upon the viral inoculum size and the time of addition of the compound with respect to infection. Virion synthesis and viral polypeptide synthesis were inhibited by addition of tromantadine at the time of infection or 4 h postinfection. The results are consistent with tromantadine inhibition of an early event in herpes simplex virus infection, before marcomolecular synthesis, and a late event, such as assembly or release of virus.

Original languageEnglish (US)
Pages (from-to)1031-1036
Number of pages6
JournalUnknown Journal
Issue number6
StatePublished - 1982
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases


Dive into the research topics of 'Tromantadine: Inhibitor of early and late events in herpes simplex virus replication'. Together they form a unique fingerprint.

Cite this